Add 2 More Reports For 20% off

Report Overview

Studies reveal that 9.5% of the global population is affected by liver fibrosis, with males having a higher prevalence of getting affected than females. The prevalence in males is around 10.6% while 5.4% of females may get develop the condition once in a lifetime. Moreover, the prevalence increases with age. Therefore, there is a significant emphasis on developing quality medications that help in disease management effectively.

  • Major companies involved in the liver fibrosis pipeline drugs market include Gilead Sciences, Intercept Pharmaceuticals and Bristol-Myers Squibb (BMS).
  • Leading drugs currently under pipeline include tirzepatide, and ALG-055009 among others.
  • Regulatory authorities such as the United States FDA and EMA play an essential role in liver fibrosis treatment as they are offering breakthrough designations to manage the condition.

Report Coverage

The Liver Fibrosis Drug Pipeline Report by Expert Market Research gives comprehensive insights into liver fibrosis drugs currently undergoing liver fibrosis clinical trials. It covers various aspects related to the details of each of these liver fibrosis drugs under development for Liver fibrosis. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The liver fibrosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from liver fibrosis.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing liver fibrosis pipeline development activities. Moreover, liver fibrosis collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.

Liver Fibrosis Drug Pipeline Outlook

Liver fibrosis  involves the formation of scar tissues in large amounts, formed as a response to repairing and replacing damaged liver cells. There are different levels of liver fibrosis which are primarily based on the degree of liver damage. The condition does not have many symptoms in the mild to moderate stages. As the patient progresses, they may encounter symptoms like appetite loss, difficulty thinking clearly, fluid buildup in the legs or stomach, jaundice (where the skin and eyes appear yellow nausea, unexplained weight loss or weakness.

Nonalcoholic fatty liver disease (NAFLD) is the most common category of liver fibrosis, followed by alcoholic liver disease, which is due to long-term excesses of drinking alcohol. The liver fibrosis treatment varies based on the cause of illness and the symptoms of the patient. Some of the specific treatment alternatives include ACE inhibitors, direct-action antivirals, PPAR-alpha agonists and antifibrotics. Several universities and pharmaceutical companies are collaborating to develop high-efficacy drugs that manage the condition effectively. In March 2024, the United States FDA granted approval to Rezdiffra (resmetirom) for treating adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis). Such approvals indicate a promising landscape for the drugs in the disease pipeline.

Liver Fibrosis – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of liver fibrosis drug candidates based on several segmentations including:

By Phase

EMR’s pipeline assessment report covers 50+ drug analyses based on phase.

  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

By Drug Class

EMR’s liver fibrosis therapeutic assessment report covers 50+ drug analyses based on drug classes:

  • Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonists
  • ACE Inhibitors
  • Hepatotropic Drugs
  • Others

By Route of Administration

EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.

  • Oral
  • Parenteral
  • Others

Liver Fibrosis – Pipeline Assessment Segmentation, By Phases

The liver fibrosis report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for liver fibrosis. There are around 334 drugs in phase II of liver fibrosis drugs.

Liver Fibrosis – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under liver fibrosis pipeline analysis include peroxisome proliferator-activated receptors (PPAR)-alpha agonists, ACE inhibitors, hepatotropic drugs and others. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for liver fibrosis.

Liver Fibrosis Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR liver fibrosis drug report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Liver fibrosis clinical trials:

  • Eli Lilly and Company
  • Gilead Sciences
  • Intercept Pharmaceuticals
  • Galectin Therapeutics
  • Genfit
  • Madrigal Pharmaceuticals
  • Bristol-Myers Squibb (BMS)
  • Novo Nordisk

Liver Fibrosis – Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for liver fibrosis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of liver fibrosis drug candidates.

Tirzepatide

Previously approved for treating type 2 diabetes, Eli Lilly's metabolic disorder medication tirzepatide, currently under phase 2 clinical trial of a 52-week study demonstrated high efficacy against nonalcoholic steatohepatitis (NASH) with no worsening of the liver fibrosis.

ALG-055009

Aligos Therapeutics is conducting a Phase 2a study to investigate the safety, tolerability, efficacy...

*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*

Reasons To Buy This Report

The Liver Fibrosis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for liver fibrosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into liver fibrosis collaborations, regulatory environments, and potential growth opportunities within liver fibrosis pipeline insights.

Key Questions Answered in the Liver Fibrosis – Pipeline Insight Report

  • Which companies/institutions are leading the liver fibrosis drug development?
  • What is the efficacy and safety profile of liver fibrosis pipeline drugs?
  • Which company is leading the liver fibrosis pipeline development activities?
  • What is the current liver fibrosis commercial assessment?
  • What are the opportunities and challenges present in the liver fibrosis drug pipeline landscape?
  • What is the efficacy and safety profile of liver fibrosis pipeline drugs?
  • Which company is conducting major trials for liver fibrosis drugs?
  • Which companies/institutions are involved in liver fibrosis collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in liver fibrosis?

Related Reports

Liver Fibrosis Market

Liver Disease Treatment Market

Global Clinical Trials Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Scope of the Report

Details

Drug Pipeline by Clinical Trial Phase

  • Late-Stage Products (Phase III and Phase IV)
  • Mid-Stage Products (Phase II)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

Route of Administration

  • Oral
  • Parenteral
  • Others

Drug Classes

  • Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonists
  • ACE Inhibitors
  • Hepatotropic Drugs
  • Others

Leading Sponsors Covered

  • Eli Lilly and Company
  • Gilead Sciences
  • Intercept Pharmaceuticals
  • Galectin Therapeutics
  • Genfit
  • Madrigal Pharmaceuticals
  • Bristol-Myers Squibb (BMS)
  • Novo Nordisk

Geographies Covered

  • North America
  • Europe
  • Asia Pacific
  • Others

Mini Report

10 % Off

USD

1,999

1,799

Single User License

10 % Off

USD

3,099

2,789

Five User License

15 % Off

USD

4,599

3,909

Corporate License

15 % Off

USD

5,999

5,099

Mini Report

One User

USD 1,999

USD 1,799

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 3,099

USD 2,789

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 4,599

USD 3,909

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 5,999

USD 5,099

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124